Journal article

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors

Sara Charmsaz, Andrew M Scott, Andrew W Boyd

EXPERIMENTAL HEMATOLOGY | ELSEVIER SCIENCE INC | Published : 2017

Abstract

The use of monoclonal antibodies (mAbs) and molecules derived from them has achieved considerable attention and success in recent years, establishing this mode of therapy as an important therapeutic strategy in many cancers, in particular hematological tumors. mAbs recognize cell surface antigens expressed on target cells and mediate their function through various mechanisms such as antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, or immune system modulation. The efficacy of mAb therapy can be improved when they are conjugated to a highly potent payloads, including cytotoxic drugs and radiolabeled isotopes. The Eph family of proteins has received considerable atte..

View full abstract

University of Melbourne Researchers

Grants

Awarded by National Health and Medical Research Council (NHMRC; Australia)


Funding Acknowledgements

The authors dedicate this review to the late Martin Lackmann, who was a driving force in the development of EphA3 antibody immunotherapy. This work was supported by grants from the Leukaemia Foundation (Australia), the Rio Tinto Ride to Conquer Cancer (Australia), the National Health and Medical Research Council (NHMRC Grant 1092788; Australia), and the Operational Infrastructure Support Program from the Victorian Government, Australia. AMS is supported by an NHMRC Senior Practitioner Fellowship (Australia).